SlideShare a Scribd company logo
Presenter Name, Institution, Country
Lung cancer cell dynamics significantly depended on
blood cell circuit, biochemical factors, hemostasis
system, cancer characteristics and anthropometric data
Oleg Kshivets, MD, PhD Surgery Department, Roshal Hospital, Roshal, Moscow, Russia
e-mail: okshivets@yahoo.com
OBJECTIVE: We examined factors significantly affecting lung cancer (LC) cell dynamics.
METHODS: We analyzed data of 768 consecutive non-small cell LC patients (LCP)
(age=57.6±8.3 years; tumor size=4.1±2.4 cm) radically operated and monitored in 1985-2022
(m=660, f=108; upper lobectomies=277, lower lobectomies=177, middle lobectomies=18,
bilobectomies=42, pneumonectomies=254, mediastinal lymph node dissection=768;
combined procedures with resection of trachea, carina, atrium, aorta, VCS, vena azygos,
pericardium, liver, diaphragm, ribs, esophagus=193; only surgery-S=618, adjuvant
chemoimmunoradiotherapy-AT=150: CAV/gemzar + cisplatin + thymalin/taktivin +
radiotherapy 45-50Gy; T1=320, T2=255, T3=133, T4=60; N0=516, N1=131, N2=121, M0=768;
G1=194, G2=243, G3=331; squamous=417, adenocarcinoma=301, large cell=50; early LC=214,
invasive LC=554; right LC=412, left LC=356; central=290; peripheral=478. Variables selected
for study were input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size.
Regression modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks
computing were used to determine significant dependence.
RESULTS: Overall life span (LS) was 2244.9±1750.3 days and cumulative 5-year survival
(5YS) reached 72.9%, 10 years – 64.3%, 20 years – 43.1%. 502 LCP lived more than 5 years
(LS=3128.7±1536.8 days), 145 LCP – more than 10 years (LS=5068.5±1513.2 days).199 LCP
died because of LC (LS=562.7±374.5 days). Regression modeling displayed LC cell dynamics
significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT
N0—N12, histology, T, G, LC growth, cell ratio factors (ratio between cancer cells- CC and
blood cells subpopulations), ESS, glucose, bilirubin (P=0.000-0.033). Neural networks
simulation revealed relationships between LC cell dynamics and segmented neutrophils
(rank=1), lymphocytes (2), PT N0—N12 (3), PT early-invasive LC (4), leucocytes (5), stick
neutrophils (6), eosinophils (7), erythrocytes (8), monocytes (9), thrombocytes (10), Hb (11),
ESS (12). Prediction was 92-95% by neural networks computing.
CONCLUSIONS: Lung cancer cell dynamics significantly depended on blood cell circuit,
biochemical factors, hemostasis system, cancer characteristics, anthropometric data.
P 96
Neural Network: n=768
Baseline Error=0.000;
Area under ROC Curve=1.000;
Correct Classification Rate 100%
Rank Sensitivity
Segmented Neutrophils 1 36514
Lymphocytes 2 23326
Phase Transition N0---N12 3 7061
Phase Transition Early---Invasive Lung Cancer 4 6652
Leucocytes 5 6168
Stick Neutrophils 6 5118
Eosinophils 7 5178
Erythrocytes 8 4938
Monocytes 9 4559
Thrombocytes 10 3862
Hemoglobin 11 3204
ESS 12 2753
Effect
Degr. of
Freedom
Wald
Stat.
p
Intercept 1 388.4581 0.000000
Weight 1 713.3978 0.000000
Erythrocytes 1 12.4875 0.000410
Thrombocytes 1 25.3659 0.000000
Erythrocytes/Cancer Cells 1 15.5562 0.000080
Thrombocytes/Cancer Cells 1 22.0515 0.000003
Healthy Cells/Cancer Cells 1 159.6450 0.000000
ESS 1 9.3616 0.002216
Bilirubin 1 6.6739 0.009783
Recalcification Time 1 8.2326 0.004114
Thrombotest 1 4.0589 0.043939
Fibrinogen 1 6.4388 0.011165
Histology 2 8.8918 0.011727
T1-4 3 81.8715 0.000000
Phase Transition Early—Invasive Cancer 1 65.7987 0.000000
Bootstrap Simulation n=701
Significant Factors
(Number of Samples=3333)
Rank Kendall’Tau-
A
P<
Healthy Cells/Cancer Cells 1 -0.849 0.000
Erythrocytes/Cancer Cells 2 -0.800 0.000
Thrombocytes/Cancer Cells 3 -0.705 0.000
Leucocytes/Cancer Cells 4 -0.596 0.000
Segmented Neutrophils/Cancer Cells 5 -0.564 0.000
T1-4 6 0.562 0.000
Lymphocytes/Cancer Cells 7 -0.529 0.000
PT Early---Invasive Cancer 8 0.410 0.000
Monocytes/Cancer Cells 9 -0.296 0.000
ESS 10 0.242 0.000
PT N0---N12 11 0.219 0.000
Surgery Type 12 0.208 0.000
Tumor Growth 13 -0.134 0.000
Segmented Neutrophils abs 14 0.128 0.000
G1-3 15 0.118 0.000
Stick Neutrophils tot 16 0.112 0.000
Lymphocytes (%) 17 -0.108 0.000
Surgery Type 18 0.160 0.000
Protein 19 -0.159 0.000
Stick Neutrophils abs 20 0.105 0.000
Coagulation Time 20 0.104 0.000
Histology 21 -0.103 0.000
Stick Neutrophils (%) 22 0.102 0.000
Monocytes abs 23 0.102 0.000
Segmented Neutrophils tot 24 0.101 0.000
Leucocytes 25 0.098 0.001
Monocytes (%) 26 0.088 0.001
Hb 27 -0.081 0.01
Erythrocytes tot 28 -0.079 0.05
Erythrocytes 29 -0.066 0.05
Thrombocytes tot 30 0.060 0.05
Survival Function
5-Year Survival=72.9%; 10-Year survival=64.3%; 20-Year Survival=43.1%;
n=768; T1-4N0-2M0
Complete Censored
-5 0 5 10 15 20 25 30
Years after Lobectomies/Pneumonectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival of Early Lung Cancer Patients=93.9%;
10-Year Surival of Invasive Lung Cancer Patients=51.8%;
P=0.0000 by Log Rank Test
Complete Censored
0 5 10 15 20 25 30 35
Years after Lobectomies/Pneumonectomies
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
Cumulative
Proportion
Surviving
Invasive Lung Cancer, n=554
Early Lung Cancer, n=214
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival of Lung Cancer Patients with N0=78.3%;
10-Year Survival of Lung Cancer Patients with N1-2=35.2%;
P=0.0000 by Log Rank Test
Complete Censored
0 5 10 15 20 25 30 35
Years After Lobectomies/Pneumonectomies
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cumulative
Proportion
Surviving
Lung Cancer with N1-2, n=252
Lung Cancer with N0=516

More Related Content

More from Oleg Kshivets

KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
Oleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
Oleg Kshivets
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
Oleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Oleg Kshivets
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
Oleg Kshivets
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
Oleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
Oleg Kshivets
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
Oleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
Oleg Kshivets
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
Oleg Kshivets
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
Oleg Kshivets
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
Oleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
Oleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
Oleg Kshivets
 

More from Oleg Kshivets (20)

KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
• Gastric cancer prognosis and cell ratio factors
•	Gastric cancer prognosis and cell ratio factors           •	Gastric cancer prognosis and cell ratio factors
• Gastric cancer prognosis and cell ratio factors
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 

Lung cancer cell dynamics significantly depended on blood cell circuit, biochemical factors, hemostasis system, cancer characteristics and anthropometric data

  • 1. Presenter Name, Institution, Country Lung cancer cell dynamics significantly depended on blood cell circuit, biochemical factors, hemostasis system, cancer characteristics and anthropometric data Oleg Kshivets, MD, PhD Surgery Department, Roshal Hospital, Roshal, Moscow, Russia e-mail: okshivets@yahoo.com OBJECTIVE: We examined factors significantly affecting lung cancer (LC) cell dynamics. METHODS: We analyzed data of 768 consecutive non-small cell LC patients (LCP) (age=57.6±8.3 years; tumor size=4.1±2.4 cm) radically operated and monitored in 1985-2022 (m=660, f=108; upper lobectomies=277, lower lobectomies=177, middle lobectomies=18, bilobectomies=42, pneumonectomies=254, mediastinal lymph node dissection=768; combined procedures with resection of trachea, carina, atrium, aorta, VCS, vena azygos, pericardium, liver, diaphragm, ribs, esophagus=193; only surgery-S=618, adjuvant chemoimmunoradiotherapy-AT=150: CAV/gemzar + cisplatin + thymalin/taktivin + radiotherapy 45-50Gy; T1=320, T2=255, T3=133, T4=60; N0=516, N1=131, N2=121, M0=768; G1=194, G2=243, G3=331; squamous=417, adenocarcinoma=301, large cell=50; early LC=214, invasive LC=554; right LC=412, left LC=356; central=290; peripheral=478. Variables selected for study were input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size. Regression modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine significant dependence. RESULTS: Overall life span (LS) was 2244.9±1750.3 days and cumulative 5-year survival (5YS) reached 72.9%, 10 years – 64.3%, 20 years – 43.1%. 502 LCP lived more than 5 years (LS=3128.7±1536.8 days), 145 LCP – more than 10 years (LS=5068.5±1513.2 days).199 LCP died because of LC (LS=562.7±374.5 days). Regression modeling displayed LC cell dynamics significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, histology, T, G, LC growth, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), ESS, glucose, bilirubin (P=0.000-0.033). Neural networks simulation revealed relationships between LC cell dynamics and segmented neutrophils (rank=1), lymphocytes (2), PT N0—N12 (3), PT early-invasive LC (4), leucocytes (5), stick neutrophils (6), eosinophils (7), erythrocytes (8), monocytes (9), thrombocytes (10), Hb (11), ESS (12). Prediction was 92-95% by neural networks computing. CONCLUSIONS: Lung cancer cell dynamics significantly depended on blood cell circuit, biochemical factors, hemostasis system, cancer characteristics, anthropometric data. P 96 Neural Network: n=768 Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate 100% Rank Sensitivity Segmented Neutrophils 1 36514 Lymphocytes 2 23326 Phase Transition N0---N12 3 7061 Phase Transition Early---Invasive Lung Cancer 4 6652 Leucocytes 5 6168 Stick Neutrophils 6 5118 Eosinophils 7 5178 Erythrocytes 8 4938 Monocytes 9 4559 Thrombocytes 10 3862 Hemoglobin 11 3204 ESS 12 2753 Effect Degr. of Freedom Wald Stat. p Intercept 1 388.4581 0.000000 Weight 1 713.3978 0.000000 Erythrocytes 1 12.4875 0.000410 Thrombocytes 1 25.3659 0.000000 Erythrocytes/Cancer Cells 1 15.5562 0.000080 Thrombocytes/Cancer Cells 1 22.0515 0.000003 Healthy Cells/Cancer Cells 1 159.6450 0.000000 ESS 1 9.3616 0.002216 Bilirubin 1 6.6739 0.009783 Recalcification Time 1 8.2326 0.004114 Thrombotest 1 4.0589 0.043939 Fibrinogen 1 6.4388 0.011165 Histology 2 8.8918 0.011727 T1-4 3 81.8715 0.000000 Phase Transition Early—Invasive Cancer 1 65.7987 0.000000 Bootstrap Simulation n=701 Significant Factors (Number of Samples=3333) Rank Kendall’Tau- A P< Healthy Cells/Cancer Cells 1 -0.849 0.000 Erythrocytes/Cancer Cells 2 -0.800 0.000 Thrombocytes/Cancer Cells 3 -0.705 0.000 Leucocytes/Cancer Cells 4 -0.596 0.000 Segmented Neutrophils/Cancer Cells 5 -0.564 0.000 T1-4 6 0.562 0.000 Lymphocytes/Cancer Cells 7 -0.529 0.000 PT Early---Invasive Cancer 8 0.410 0.000 Monocytes/Cancer Cells 9 -0.296 0.000 ESS 10 0.242 0.000 PT N0---N12 11 0.219 0.000 Surgery Type 12 0.208 0.000 Tumor Growth 13 -0.134 0.000 Segmented Neutrophils abs 14 0.128 0.000 G1-3 15 0.118 0.000 Stick Neutrophils tot 16 0.112 0.000 Lymphocytes (%) 17 -0.108 0.000 Surgery Type 18 0.160 0.000 Protein 19 -0.159 0.000 Stick Neutrophils abs 20 0.105 0.000 Coagulation Time 20 0.104 0.000 Histology 21 -0.103 0.000 Stick Neutrophils (%) 22 0.102 0.000 Monocytes abs 23 0.102 0.000 Segmented Neutrophils tot 24 0.101 0.000 Leucocytes 25 0.098 0.001 Monocytes (%) 26 0.088 0.001 Hb 27 -0.081 0.01 Erythrocytes tot 28 -0.079 0.05 Erythrocytes 29 -0.066 0.05 Thrombocytes tot 30 0.060 0.05 Survival Function 5-Year Survival=72.9%; 10-Year survival=64.3%; 20-Year Survival=43.1%; n=768; T1-4N0-2M0 Complete Censored -5 0 5 10 15 20 25 30 Years after Lobectomies/Pneumonectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival of Early Lung Cancer Patients=93.9%; 10-Year Surival of Invasive Lung Cancer Patients=51.8%; P=0.0000 by Log Rank Test Complete Censored 0 5 10 15 20 25 30 35 Years after Lobectomies/Pneumonectomies -0.2 0.0 0.2 0.4 0.6 0.8 1.0 Cumulative Proportion Surviving Invasive Lung Cancer, n=554 Early Lung Cancer, n=214 Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival of Lung Cancer Patients with N0=78.3%; 10-Year Survival of Lung Cancer Patients with N1-2=35.2%; P=0.0000 by Log Rank Test Complete Censored 0 5 10 15 20 25 30 35 Years After Lobectomies/Pneumonectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Lung Cancer with N1-2, n=252 Lung Cancer with N0=516